LGR-5 as a Biomarker in Colorectal Cancer: A Systematic Review of Clinicopathological Features and Prognostic Value
Analysis
DOI:
https://doi.org/10.55175/cdk.v52i3.1282Keywords:
Colorectal Cancer, LGR5, Marker, PrognosisAbstract
Colorectal cancer (CRC) had the third highest cancer incidence worldwide. Recent researches are targeting specific gene expression as CRC marker. Leucine rich repeat-containing G-protein coupled receptor 5 (LGR5) is one of the genes that regulate tumor metastasis and growth. The aim of this study is to explain the correlation between LGR5, clinical pathology, and prognosis of CRC. This systematic review was arranged using PRISMA for eligible cohort studies and evaluated using Newcastle-Ottawa scale. From 63 articles, 6 articles were selected as eligible articles for data extraction and evaluation. Based on the studies, LGR5 positivity was positively associated with histopathological characteristics, TNM staging, and vascular invasion. Besides, LGR5 expressions in those studies were high and could be positively detected by this marker. LGR5 regulates Wnt/β-catenin signaling pathway promotion in normal colon stem cell. Methylation of Wnt target gene promoter is potent predictor to CRC recurrence thus the expression of LGR5 can be used as CRC marker. LGR5 plays a role as pro-oncogenic factor in colorectal carcinogenesis via prostaglandin E2 and Epidermal Growth Factor signaling. LGR5 induction also could increase cancer cells chemoresistant ability. Thus, LGR5 could determine prognosis of CRC patient and were related to certain clinicopathological features and tumor progressions.
Downloads
References
Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA. Immunotherapy for gastrointestinal malignancies. Cancer Control. 2013;20(1):32–42. DOI: 10.1177/107327481302000106.
Sudoyo AW, Setiyohadi B, Alwi I, K MS, Setiati S. Buku ajar ilmu penyakit dalam Jilid 1. 4th Ed. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Universitas Indonesia; 2014.
Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7(3):105–14. PMID: 27766137.
Akduran F, Cinar N. Effects of nursing education on awareness of risk factors for colorectal cancer. Asian Pac J Cancer Prev. 2015;16(14):5763–6. DOI: 10.7314/apjcp.2015.16.14.5763.
Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: Epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15(3):195–203. DOI: 10.1016/j.clcc.2016.02.008.
Toma M, Belusica L, Stavarachi M, Apostol P, Spandole S, Radu I, et al. Rating the environmental and genetic risk factors for colorectal cancer. J Med Life. 2012;5(Spec Issue):152–9. PMID: 31803304.
Steinke V, Engel C, Buttner R, Schackert HK, Schmiegel WH, Propping P. Hereditary nonpolyposis colorectal cancer (HNPCC)/lynch syndrome. Dtsch Arztebl Int. 2013;110(3):32–8. DOI: 10.3238/arztebl.2013.0032.
Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 2012 Sep;27(9):1423–31. DOI: 10.1111/j.1440-1746.2012.07200.x.
Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: Pathologic aspects. J Gastrointest Oncol. 2012;3(3):153–73. DOI: 10.3978/j.issn.2078-6891.2012.030.
Jang BG, Kim HS, Chang WY, Bae JM, Kim WH, Kang GH. Expression profile of LGR5 and its prognostic significance in colorectal cancer progression. Am J Pathol. 2018;188(10):2236–50. DOI: 10.1016/j.ajpath.2018.06.012.
Ihemelandu C, Naeem A, Parasido E, Berry D, Chaldekas K, Harris BT, et al. Clinicopathologic and prognostic significance of LGR5, a cancer stem cell marker in patients with colorectal cancer. Colorectal Cancer. 2019;8(4):CRC11. DOI: 10.2217/crc-2019-0009.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI: 10.1136/bmj.n71.
Shekarriz R, Montazer F, Alizadeh-Navaei R. Overexpression of cancer stem cell marker Lgr5 in colorectal cancer patients and association with clinicopathological findings. Caspian J Intern Med. 2019;10(4):412–6. DOI: 10.22088/cjim.10.4.411.
Zheng Z, Yu H, Huang Q, Wu H, Fu Y, Shi J, et al. Heterogeneous expression of Lgr5 as a risk factor for focal invasion and distant metastasis of colorectal carcinoma. Oncotarget. 2018;9(53):30025–33. DOI: 10.18632/oncotarget.23144.
Gzil A, Zarębska I, Jaworski D, Antosik P, Durślewicz J, Maciejewska J, et al. The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer. J Cancer Res Clin Oncol. 2020;146(10):2547–57. DOI: 10.1007/s00432-020-03314-7.
Harb O, Hegazy A, Gertallah L, Haggag R, Mostafa S. Prognostic value of immunohistochemical expressions of the stem cell biomarker “LGR5” and the proliferation biomarker “TPX2” in colorectal carcinoma: Harb OA et al. LGR5 and TPX2 in colorectal carcinoma. Journal of Tumor. 2016;4:426–34. DOI:10.17554/j.issn.1819-6187.2016.04.93.
Fan XS, Wu HY, Yu HP, Zhou Q, Zhang YF, Huang Q. Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with beta-catenin. Int J Colorectal Dis. 2010;25(5):583–90. DOI: 10.1007/s00384-010-0903-z.
Xu L, Lin W, Wen L, Li G. Lgr5 in cancer biology: Functional identification of Lgr5 in cancer progression and potential opportunities for novel therapy. Stem Cell Res Ther. 2019;10:219. DOI: 10.1186/s13287-019-1288-8.
Tan J, Chen YX. Dietary and lifestyle factors associated with colorectal cancer risk and interactions with microbiota: Fiber, red or processed meat and alcoholic drinks. Gastrointest Tumors. 2016 Sep;3(1):17–24. DOI: 10.1159/000442831.
Carmon KS, Gong X, Lin Q, Thomas A, Liu QJ. R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/$β$-catenin signaling. Proc Natl Acad Sci. 2011;108:11452–7. DOI: 10.1073/pnas.1106083108.
de Lau W, Barker N, Low TY, Koo BK, Li VSW, Teunissen H, et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 2011;476(7360):293–7. DOI: 10.1038/nature10337.
Glinka A, Dolde C, Kirsch N, Huang YL, Kazanskaya O, Ingelfinger D, et al. LGR4 and LGR5 are R-spondin receptors mediating Wnt/β-catenin and Wnt/PCP signalling. EMBO Rep. 2011;12(10):1055–61. DOI: 10.1038/embor.2011.175.
Takahashi H, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M, et al. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol. 2011;18(4):1166–74. DOI: 10.1245/s10434-010-1373-9.
Morgan RG. Targeting LGR5 in colorectal cancer: Therapeutic gold or too plastic? Br J Cancer 2018;118:1410-8. DOI: 10.1038/s41416-018-0118-6.
Al-Kharusi MRA, Smartt HJM, Greenhough A, Collard TJ, Emery ED, Williams AC, et al. LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis. 2013;34(5):1150–7. DOI: 10.1093/carcin/bgt020.
Morgan RG, Mortensson E, Legge DN, Gupta B, Collard TJ, Greenhough A, et al. LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity. Br J Cancer. 2018;118(4):558–65. DOI: 10.1038/bjc.2017.412.
Hsu HC, Liu YS, Tseng KC, Hsu CL, Liang Y, Yang TS, et al. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Int J Colorectal Dis. 2013;28(11):1535–46. DOI: 10.1007/s00384-013-1721-x.
Carmon KS, Gong X, Yi J, Wu L, Thomas A, Moore CM, et al. LGR5 receptor promotes cell-cell adhesion in stem cells and colon cancer cells via the IQGAP1-Rac1 pathway. J Biol Chem. 2017;292(36):14989–5001. DOI: 10.1074/jbc.M117.786798.
Walker F, Zhang HH, Odorizzi A, Burgess AW. LGR5 is a negative regulator of tumourigenicity, antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines. PLoS One. 2011;6(7):e22733. DOI: 10.1371/journal.pone.0022733.
Leng Z, Xia Q, Chen J, Li Y, Xu J, Zhao E, et al. Lgr5+CD44+EpCAM+ strictly defines cancer stem cells in human colorectal cancer. Cell Physiol Biochem. 2018;46(2):860–72. DOI: 10.1159/000488743.
He S, Zhou H, Zhu X, Hu S, Fei M, Wan D, et al. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. Biomed Pharmacother. 2014;68(5):507–13. DOI: 10.1016/j.biopha.2014.03.016.
Wu XS, Xi HQ, Chen L. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol. 2012;10:244. DOI: 10.1186/1477-7819-10-244.
Chen Q, Zhang X, Li WM, Ji YQ, Cao HZ, Zheng P. Prognostic value of LGR5 in colorectal cancer: a meta-analysis. PLoS One 2014;9(9):e107013. DOI: 10.1371/journal.pone.0107013.
Jiang Y, Li W, He X, Zhang H, Jiang F, Chen Z. Lgr5 expression is a valuable prognostic factor for colorectal cancer: evidence from a meta-analysis. BMC Cancer. 2016;16:12. DOI: 10.1186/s12885-015-1986-2.
Melling N, Kowitz CM, Simon R, Bokemeyer C, Terracciano L, Sauter G, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol. 2016;69(3):209–14. DOI: 10.1136/jclinpath-2015-202985.
Kim Y, Kang D, Song G, Ahn T, Son MW, Lee M, et al. Clinical relevance of Lgr5 expression in colorectal cancer patients. Kor J Clin Oncol. 2018;14:76–82. DOI: 10.14216/kjco.18014.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aiman Hilmi Asaduddin, Roisya Nur Farhania, Namira Putri Imani, Cindy Ayudia Pramaesti, Andayani Yuwana Sari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
